Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company, has secured $120 million in Series B financing. Venrock Healthcare Capital Partners led the round.
Source: Press Release
Artiva Biotherapeutics nets $120m Series B
Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company, has secured $120 million in Series B financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: